Guideline proposal for pharma companies to manage pharmacovigilance activities in digital media

Authors

  • Daniela Bernardini Novartis Farma, Origgio (VA) - Italy
  • Ilenia Bocchi Bayer, Milan - Italy
  • Stefano Bonato Bayer, Milan - Italy
  • Davide Bottalico Takeda Italia, Rome - Italy
  • Valentina Calderazzo Boehringer Ingelheim Italia, Milan - Italy
  • Carmela Casino Servier Italia, Rome - Italy
  • Gian Nicola Castiglione Chiesi Farmaceutici, Parma - Italy
  • Carla Cottone Teva Italia, Assago (MI) - Italy
  • Stefania Dellon Neopharmamed Gentili, Milan - Italy
  • Ilaria Grisoni Jazz Pharmaceuticals, Villa Guardia (CO) - Italy
  • Amanda Mattavelli Janssen-Cilag, Cologno Monzese (MI) - Italy
  • Giacomo Pirisino Astellas Pharma, Milan - Italy
  • Silvia Romano Sanofi Pasteur Vaccines Italy and Malta, Milan - Italy
  • Grazia Sirizzotti Biogen Italia, Milan - Italy
  • Lisa Stagi Roche, Monza (MB) - Italy
  • on behalf of the SIMeF Working Group

DOI:

https://doi.org/10.33393/ao.2022.2401

Keywords:

Adverse events, Artificial intelligence, Digital activities, Pharmacovigilance, Social media

Abstract

Internet has become a central part of our everyday lives. Digital media are integrated in our daily routines and play a critical role in the dissemination of public health information and disease prevention guidelines. For this reason, digital activities are becoming more and more impacting in pharma company activities and this is an increasing trend after the pandemic period. Managing digital activities from pharmacovigilance (PV) perspective may have challenges linked to correct assessment of the activities and application of PV rules: this was underlined in recent publications, where the need to have more specific guidelines linked to digital activities management was evidenced.

Considering this scenario and the continuous evolution of the digital activities, the SIMEF PV working group decided to work on a proposal guideline to provide support to PV departments in pharma companies, suggesting a framework to manage sponsored digital activities (i.e., website, web apps, social media webpage, chatbots) impacting potential collection of adverse events (AEs). The purpose of this guideline is to provide useful instructions on how to manage PV requirements for digital activities, suggesting potential solutions for assessing initiatives, creating governance framework, conducting a correct vendor management, and suggesting practical approaches for AEs reporting and follow-up. The aim of this document is also to trigger a broader discussion among relevant stakeholders on which PV guidelines may be useful and appropriate considering this continuous evolving scenario.

 

References

Stagi L, Bocchi I, Bianco S, et al. Pharmacovigilance and the digital world in Italy: presentation of the results of a national survey. Ther Adv Drug Saf. 2021;12:2042098620985991. https://doi.org/10.1177/2042098620985991 PMID:33623659 DOI: https://doi.org/10.1177/2042098620985991

Audeh B, Bellet F, Beyens MN, Lillo-Le Louët A, Bousquet C. Use of social media for pharmacovigilance activities: key findings and recommendations from the Vigi4Med Project. Drug Saf. 2020;43(9):835-851. https://doi.org/10.1007/s40264-020-00951-2 PMID:32557179 DOI: https://doi.org/10.1007/s40264-020-00951-2

Convertino I, Ferraro S, Blandizzi C, Tuccori M. The usefulness of listening social media for pharmacovigilance purposes: a systematic review. Expert Opin Drug Saf. 2018;17(11):1081-1093. https://doi.org/10.1080/14740338.2018.1531847 PMID:30285501 DOI: https://doi.org/10.1080/14740338.2018.1531847

Sloane R, Osanlou O, Lewis D, Bollegala D, Maskell S, Pirmohamed P. Social media and pharmacovigilance: a review of the opportunities and challenges. Br J Clin Pharmacol. 2015; 80(4):910-920. https://doi.org/10.1111/bcp.12717 DOI: https://doi.org/10.1111/bcp.12717

De Carli G. Quality assurance e farmacovigilanza. Parte II – Quality Assurance in Pharmacovigilance (ii). Giornale Italiano di Farmacoeconomia e Farmacoutilizzazione. 2015;7(1):27-35.

Brosch S, de Ferran AM, Newbould V, Farkas D, Lengsavath M, Tregunno P. Establishing a framework for the use of social media in pharmacovigilance in Europe. Drug Saf. 2019;42(8):921-930. https://doi.org/10.1007/s40264-019-00811-8 PMID:30929141 DOI: https://doi.org/10.1007/s40264-019-00811-8

Published

2022-04-21

How to Cite

1.
Bernardini D, Bocchi I, Bonato S, Bottalico D, Calderazzo V, Casino C, Castiglione GN, Cottone C, Dellon S, Grisoni I, Mattavelli A, Pirisino G, Romano S, Sirizzotti G, Stagi L, SIMeF Working Group on behalf of the. Guideline proposal for pharma companies to manage pharmacovigilance activities in digital media. abtpn [Internet]. 2022 Apr. 21 [cited 2022 Sep. 26];9(1):21-8. Available from: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2401

Issue

Section

Point of view